Pharmaceutical toxicology: Designing studies to reduce animal use, while maximizing human translation

Regulatory Toxicology and Pharmacology

Volumn 66, Issue 1, 2013, Pages 88-103

  Chapman, Kathryn L ^a   Holzgrefe, Henry ^b   Black, Lauren E ^b   Brown, Marilyn ^b   Chellman, Gary ^b   Copeman, Christine ^b   Couch, Jessica ^c   Creton, Stuart ^a   Gehen, Sean ^d   Hoberman, Alan ^b   Kinter, Lewis B ^e   Madden, Stephen ^f   Mattis, Charles ^g   Stemple, Hugh A ^h   Wilson, Stephen ^b  

^a National Centre for the Replacement   (United Kingdom)

^b CHARLES RIVER LABORATORIES   (United States)

^c GENENTECH INC   (United States)

^d DOW AGROSCIENCES LLC   (United States)

^e ASTRAZENECA   (United Kingdom)

^f CHARLES RIVER LABORATORIES   (United Kingdom)

^g ABBVIE INC   (United States)

^h Alberta Innovates Technology Futures   (Canada)

Author keywords

3Rs; Biologicals; Developmental; In vitro methods; New chemical entities; Reproductive; Rodents; Safety; Safety pharmacology; Toxicology

Indexed keywords

ARTICLE; CARCINOGENICITY; CHEMICAL INDUSTRY; DRUG INDUSTRY; FEMALE FERTILITY; GENITAL SYSTEM; HUMAN; IMMUNOTOXICITY; IN VITRO STUDY; MALE FERTILITY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; RISK ASSESSMENT; SAFETY; TOXICITY TESTING; TOXICOLOGY;

ANIMAL TESTING ALTERNATIVES; ANIMALS; HUMANS; PHARMACEUTICAL PREPARATIONS; RESEARCH DESIGN; RISK ASSESSMENT; RODENTIA; SPECIES SPECIFICITY; TOXICOLOGY; TRANSLATIONAL MEDICAL RESEARCH;

ANIMALIA; RODENTIA;

EID: 84876324600     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2013.03.001     Document Type: Article

References (68)

1. Aylward L.L., Hays S.M. Biomonitoring Equivalents (BE) dossier for 2,4-dichlorophenoxyacetic acid (2,4-D) (CAS No. 94-75-7). Regulatory Toxicology and Pharmacology 2008, 51:S37-S48.
2. Bailey G.P., Wise L.D., Buschmann J., Hurtt M., Fisher J.E. Pre- and postnatal developmental toxicity study design for pharmaceuticals. Birth Defects Research Part B: Developmental and Reproductive Toxicology 2009, 86(6):437-445.
3. Barrow P.C. Reproductive toxicity testing for pharmaceuticals under ICH. Reproductive Toxicology 2009, 28:172-179.
4. Barton H.A., Pastoor T.P., Baetcke K., Chambers J.E., Dinberto J., Doerrer N.G., Driver J.H., Hastings C.E., Iyengar S., Krieger R., Stahl B., Timchalk C. The acquisition and application of absorption, distribution, metabolism, and excretion (ADME) data in agricultural chemical safety assessments. Critical Reviews in Toxicology 2006, 36:9-35.
5. Bazett H.C. An analysis of the time relations of electrocardiograms. Heart 1920, 7:353-370.
6. Billington R., Lewis R.W., Mehta J.M., Dewhurst I. The mouse carcinogenicity study is no longer a scientifically justifiable core data requirement for the safety assessment of pesticides. Critical Reviews in Toxicology 2010, 40:35-49.
7. Brannen K.C., Panzica-Kelly J.M., Danberry T.L., Augustine-Rauch K.A. Development of a zebrafish embryo teratogenicity assay and quantitative prediction model. Birth Defects Research Part B: Developmental and Reproductive Toxicology 2010, 89(1):66-77.
8. BVA/FRAME/RSPCA/UFAW Joint Working Group on Refinement Removal of blood from laboratory mammals and birds, first Report of the joint working group. Laboratory Animals 1993, 27:1-22.
9. Carmichael N.G., Barton H.A., Boobis A.R., Cooper R.L., Dellarco V.L., Doerrer N.G., Fenner-Crisp P.A., Doe J.E., Lamb J.C.T., Pastoor T.P. Agricultural chemical safety assessment: a multisector approach to the modernization of human safety requirements. Critical Reviews in Toxicology 2006, 36:1-7.
10. Cavero I. Cardiovascular system assessment best practices: a safety pharmacology society meeting. Expert Opinion on Drug Safety 2010, 9(5):855-866.
11. Chapin R., Augustine-Rauch K., Beyer B., Daston G., Finnell R., Flynn T., Hunter S., Mirkes P., O'Shea K.S., Piersma A., Sandler D., Vanparys P., Van Maele-Fabry G. State of the art in developmental toxicity screening methods and a way forward: a meeting report addressing embryonic stem cells, whole embryo culture, and zebrafish. Birth Defects Research Part B: Developmental and Reproductive Toxicology 2008, 83(4):446-456.
12. Chellman G.J., Bussiere J.L., Makori N., Martin P.L., Ooshima Y., Weinbauer G.F. Developmental and reproductive toxicology studies in nonhuman primates. Birth Defects Research (Part B) 2009, 86:446-462.
13. Committee on Safety of Medicines; Guidance on Reproduction Studies. 1975. Medical Specialties register, UK.
14. Cooper R.L., Lamb J.C., Barlow S.M., Bentley K., Brady A.M., Doerrer N.G., Eisenbrandt D.L., Fenner-Crisp P.A., Hines R.N., Irvine L.F., Kimmel C.A., Koeter H., Li A.A., Makris S.L., Sheets L.P., Speijers G., Whitby K.E. A tiered approach to life stages testing for agricultural chemical safety assessment. Critical Reviews in Toxicology 2006, 36:69-98.
15. Creton Dewhurst.I.C., Earl L.K., Gehen S.C., Guest R.L., Hotchkiss J.A., Indans I., Woolhiser M.R., Billington R. Acute toxicity testing of chemicals opportunities to avoid redundant testing and use alternative approaches. Critical Reviews in Toxicology 2010, 40:50-83.
16. Creton S., Saghir S.A., Bartels M.J., Billington R., Bus J.S., Davies W., Dent M.P., Hawksworth G.M., Parry S., Travis K.Z. Use of toxicokinetics to support chemical evaluation: Informing high dose selection and study interpretation. Regulatory Toxicology and Pharmacology 2011, 62:241-247.
17. Croplife America website. [accessed 23rd October 2012]. http://www.croplifeamerica.org/crop-protection/pesticide-regulation.
18. Dellarco V.L., Rowland J., May B. A retrospective analysis of toxicity studies in dogs and impact on the chronic reference dose for conventional pesticide chemicals. Critical Reviews in Toxicology 2010, 40:16-23.
19. Deng R., Iyer S., Theil F.P., Mortensen D.L., Fielder P.J., Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data. mAbs 2011, 3(1):61-66.
20. Diehl K., Hull R., Morton D., et al. A good practice guide to the administration if substances and removal of blood, including routes and volumes. Journal of Applied Toxicology 2001, 21:15-23.
21. Doe J.E., Boobis A.R., Blacjer A., Delarco V., Doerrer N.G., Franklin C., Goodman J.I., Kronenberg J.M., Lewis R., McConnell E.E., Mercier T., Moretto A., Nolan C., Padilla S., Phang W., Solecki R., Tilbury L., Van Ravenzwaay B., Wolf D.C. A tiered approach to systemic toxicity testing for agricultural chemical safety assessment. Critical Reviews in Toxicology 2006, 36:37-68.
22. EEC Council Directive 76/768/EEC of 27 July 1976 on the approximation of the laws of the Member States relating to cosmetic products. Official Journal of the European Communities 1976, L262:169-172.
23. EEC Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. Official Journal of the European Communities 1986, L358:1-29.
24. Ewart L., Gallacher D.J., Gintant G., Guillon J.M., Leishman D., Levesque P., McMahon N., Mylecraine L., Sanders M., Suter W., Wallis R., Valentin J.P. How do the top 12 pharmaceutical companies operate safety pharmacology?. Journal of Pharmacology and Toxicology Methods 2012, 66(2):66-70.
25. Fridericia L.S. Die systolendauer im elektrokardiogramm bei normalen menschen und bei herzkranken. Acta Medica Scandinavica 1920, 53:469-486.
26. Geter D., Kan H.L., Wood A., et al. Phenobarbital-like mode of action for liver tumours in CD1 mice and F344 rats exposed to a new developmental compound X11422208. The Toxicologist 2011, 120(Suppl. 2 PS 223):47.
27. Glueck D.H., Muller K.E., Karimpour-Fard A., Hunter L. Expected power for the false discovery rate with independence. Communications in Statistics: Theory and Methods 2008, 37(12):1855-1866.
28. Hawk C.T., Leary S.L. Formulary for Laboratory Animals 1995, Iowa State University Press, Ames, Iowa, pp. 74, 79.
29. Holzgrefe H.H., Cavero I., Gleason C.R., et al. Novel probabilistic method for precisely correcting the QT interval for heart rate in telemetered dogs and cynomolgus monkeys. Journal of Pharmacology and Toxicology Methods 2007, 55(2):159-175.
30. ICH. S6, 1997a. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf.
31. ICH. S6, 1997a. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf.
32. ICH. M3, 1997b. Nonclinical safety studies for the conduct of human clinical trials for pharmaceuticals. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf.
33. ICH S7A, 2001. Safety pharmacology studies for human pharmaceuticals. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf.
34. ICH. S7B, 2005. The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. 2004. [accessed 6 April 2011]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf.
35. ICH, E14, 2005. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/Step4/E14_Guideline.pdf.
36. Jain, N.C., 1987. Schalm's Veterinary Hematology, 4th ed. Philadelphia Lea and Febiger.
37. Jonsson O., Palma Villar R., Nilsson L.B., Norsten-Höög C., Brogren J., Eriksson M., Königsson K., Samuelsson A. Capillary microsampling of 25μl blood for the determination of toxicokinetic parameters in regulatory studies in animals. Bioanalysis 2012, 4(6):661-674.
38. Kobel W., Fegert I., Billington R., Lewis R., Bentley K., Bomann W., Botham P., Stahl B., Van Ravenzwaay B., Spielmann H. A 1-year toxicity study in dogs is no longer a scientifically justifiable core data requirement for the safety assessment of pesticides. Critical Reviews in Toxicology 2010, 40:1-15.
39. Ladics G.S., Smith C., Heaps K., Elliott G.S., Slone T.W., Loveless S.E. Possible incorporation of an immunotoxicological functional assay for assessing humoral immunity for hazard identification purposes in rats on standard toxicology study. Toxicology 1995, 96:225-238.
40. Ladics G.S., Smith C., Elliott G.S., Slone T.W., Loveless S.E. Further evaluation of the incorporation of an immunotoxicological functional assay for assessing humoral immunity for hazard identification purposes in rats in a standard toxicology study. Toxicology 1998, 126:137-152.
41. Leishman D.J., Beck T.W., Dybdal N., et al. Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: current recommendations from the safety pharmacology society. Journal of Pharmacology and Toxicology Methods 2012, 65:93-101.
42. Lewis E.M., Barnett J.F., Freshwater L., Hoberman A.H., Christian M.S. Sexual maturation data for CRL Sprague-Dawley rats: criteria and confounding factors. Drug and Chemical Toxicology 2002, 25(4):437-458.
43. Louhimies S. Directive 86/609/EEC on the protection of animals used for experimental and other scientific purposes. ATLA 2002, 30(Suppl. 2):217-219.
44. McGuill M.W. Rowan AN (1989) biological effects of blood loss: implications for sampling volumes and techniques. Perspectives on Animal Use 1989, 31(4):5-18.
45. Moller C. Keeping the rhythm, hERG and beyond in cardiovascular safety pharmacology. Expert Review of Clinical Pharmacology 2010, 3:321-329.
46. OECD, 2011. OECD Test Guideline 433: Extended One-Generation Reproduction Toxicity Study.
47. Peers I.S., Ceuppens P.R., Harbron C. In search of preclinical robustness. Nature Reviews Drug Discovery 2012, 11(10):733-734.
48. Piccini J.P., Whellan D.J., Berridge B.R., Finkle J.K., Pettit S.D., Stockbridge N., Valentin J.P., Vargas H.M., Krucoff M.W. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the critical path initiative. American Heart Journal 2009, 158:317-326.
49. Podolsky, M.L., Lukas, V.S., 1998. The Care and Feeding of an IACUC. Guidelines for Blood Sample Withdrawal, CRC press, pp. 185-186.
50. Price C., Stallard N., Creton S., Indans I., Guest R.L., Griffiths D., Edwards P. A statistical evaluation of the effects of sex differences in assessment of acute inhalation toxicity. Human and Experimental Toxicology 2011, 30:217-238.
51. Rasoulpour R.J., Ellis-Hutchings R.G., Terry C., Millar N.S., Zablotny C.L., Gibb A., Marshall V., Collins T., Carney E.W., Billington R. A novel mode-of-action mediated by the fetal muscle nicotinic acetylcholine receptor resulting in developmental toxicity in rats. Toxicological Science 2012, 127(2):522-534.
52. Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), Regulation (EC) no 1907/2006 of the European Parliament and of the Council concerning REACH establishing a European Chemicals Agency, amending Directive 1999/45/EC of the European Parliament and of the Council and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) no 1488/94, as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC.
53. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K., Strang I., Sullivan A.T., Wallis R., Camm A.J., Hammond T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovascular Research 2003, 58:32-45.
54. Russell W.M.S., Burch R.L. The Principles of Humane Experimental Technique 1959, Methuen, London.
55. Schumann R. The Seventh amendment to the cosmetics directive: what does DG enterprise want from ECVAM?. ATLA 2002, 30(Suppl. 2):213-214.
56. Seidle T., Robinson S., Holmes T., Creton S., Prieto P., Scheel J., Chlebus M. Cross-sector review of drivers and available 3Rs approaches for acute systemic toxicity testing. Toxicological Sciences 2010, 116:382-396.
57. Sparrow S.S., Robinson S., Bolam S., Bruce C., Danks A., Everett D., Fulcher S., Hill R.E., Palmer H., Scott E.W., Chapman K.L. Opportunities to minimise animal use in pharmaceutical regulatory general toxicology: a cross-company review. Regulatory Toxicology and Pharmacology 2011, 61(2):222-229.
58. Spooner N. Dried blood spot sampling for quantitative bioanalysis: time for a revolution?. Bioanalysis 2010, 2(11):1781.
59. Stallard N., Price C., Creton S., et al. A new sighting study for the fixed concentration procedure to allow for gender differences. Human Experimental Toxicology 2012, 30:239-249.
60. Stephens M.L., Goldberg A.M., Rowan A.N. The First Forty Years of Alternatives Approach: Refining, Reducing, and Replacing the Use of Laboratory Animals. The State of Animals 2001, 121-135. Humane Society Press, Washington, DC. D.J. Salem, A.N. Rowan (Eds.).
61. Stewart J. Developmental toxicity testing of monoclonal antibodies: an enhanced pre- and postnatal study design option. Reproductive Toxicology 2009, 28:220-225.
62. Tanimura, T., Kameyama, Y., Shiota, K., Tanaka, S., Matsumoto, N., Mizutani, M., 1989. Report on the review of the guidelines for studies of the effect of drugs on reproduction. Notification No. 118, Pharmaceutical Affairs Bureau, Ministry of Health and Welfare, Japan.
63. Terry C., Rasoulpour R.J., Gollapudi B., Billington R. An integrated approach based on the ''3'' principles of animal welfare and sound science. Toxicology Letters 2011, 205S(S244).
64. U.S. Environmental Protection Agency Title 40 Code of Federal Regulations Part 158: Data requirements for registration 2007, U.S. Government Printing Office, Washington, DC.
65. U.S. Food and Drug Administration (FDA), 1966. Guidelines for Reproduction Studies for Safety Evaluation of Drugs for Human Use. US, FDA.
66. US National Research Council (NRC) Committee on Toxicity and Assessment of Environmental Agents, 2007. Toxicity testing in the 21st century: a vision and a strategy. Washington, DC. Available at:. http://dels.nas.edu/dels/rpt_briefs/Toxicity_Testing_final.pdf.
67. Valentin J.P., Bialecki R., Ewart L., Hammond T., Leishmann D., Lindgren S., Martinez V., Pollard C., Redfern W., Wallis R. A framework to assess the translation of safety pharmacology data to humans. Journal of Pharmacology and Toxicology Methods 2009, 60(2):152-158.
68. Van Herck H., Baumans V., Van Der Craats N.R., Hesp A.P.M., Meijer G.W., Van Tintelen G., Walvoort H.C., Beynen A.C. Histological changes in the orbital region of rats after orbital puncture. Laboratory Animals 1992, 26:53-58.